People taking GLP-1 medications report fingernail loss in new study

Key Points:

• Research presented at the European Academy of Dermatology and Venereology Congress 2026 found that people taking GLP-1 medications for obesity or diabetes report significantly higher rates of nail detachment, discoloration, and hair loss compared to non-users with similar health profiles.
• In a study of 575 GLP-1 users and 1,329 non-users, 39% of GLP-1 users experienced nail detachment versus 9% of non-users, and 66% of GLP-1 users reported at least one nail disorder compared to 53% of the control group, with weight loss not fully explaining these differences.
• Hair and scalp conditions were also more prevalent among GLP-1 users, with 50% reporting unusual hair loss compared to 34% of non-users, and inflammatory scalp symptoms such as redness and itching were common, suggesting an inflammatory component beyond typical shedding from weight loss.
• Researchers caution that these findings show associations but do not prove causation, as the data was self-reported and cross-sectional; patients experiencing symptoms are advised to consult physicians rather than discontinue medication.
• Further studies are planned to explore the timing, causes, and duration of these dermatological changes, with institutional support from DUCRAY Laboratories; GLP-1 manufacturers were contacted for comment.